Harjit Gill
RESMEDAbout Harjit Gill
Independent director at ResMed (RMD) since 2018; age 60 as of the 2025 record date. She is CEO of the Asia Pacific Medical Technology Association (APACMed) and brings deep international consumer healthcare, sales, marketing, and compliance expertise across Europe, Asia and the Middle East. Education: B.A. (Hons) Combined Studies, University of Manchester. She chairs ResMed’s Compliance, Privacy & Quality Committee and also serves on the Audit and Compensation & Leadership Development Committees .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Royal Philips (NYSE: PHG) | Progressive leadership roles incl. EVP and CEO for Philips ASEAN & Pacific | 1990–2015 | Extensive international operating leadership in consumer healthcare, sales, and marketing . |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Asia Pacific Medical Technology Association (APACMed) | Chief Executive Officer | Feb 2019–Present | Leads regional medtech compliance, privacy, and quality dialogue; aligns with chair role at ResMed’s CPQ Committee . |
| Alticor Inc. (Amway holding company) | Director | Jan 2022–Present | Member, Audit Committee . |
| MAS Holdings | Member, Innovation Board of Directors | 2019–Present | Innovation oversight at major apparel tech manufacturer . |
| Peking University (China-ASEAN public health center) | Member, Academic Committee | Not disclosed | Academic committee member for public health cooperation . |
Board Governance
- Independence: Board determined Ms. Gill is independent under NYSE and ASX standards; all committee members (including Audit and Compensation) are independent and meet enhanced standards for those committees .
- Committee roles: Chair, Compliance, Privacy & Quality (CPQ); Member, Audit; Member, Compensation & Leadership Development .
- Attendance and engagement: FY2025 attendance was 100% for all directors except Peter Farrell (post-surgery travel); CPQ held 5 meetings (including compliance oversight) with 100% attendance; Audit held 8 meetings with 100% attendance; Compensation & Leadership Development held 4 meetings with 100% attendance .
- Executive sessions & independent oversight: Independent directors meet in executive session at each board meeting, led by the Lead Director (Ronald Taylor) .
- Committee scope: CPQ committee expanded in 2025 to include global compliance, privacy, quality, sustainability, and employee safety; chaired by Gill .
Fixed Compensation (Director)
| Item | Detail | FY2025 Amount |
|---|---|---|
| Annual cash retainer | Non-executive director retainer | $70,000 . |
| Committee chair fee | Compliance, Privacy & Quality (CPQ) chair | $15,000 . |
| FY2025 cash paid (actual) | Includes pro-rated chair retainer due to chair transition timing | $73,190 . |
| FY2026 retainer change | Non-executive director retainer increase effective July 1, 2025 | $75,000 (from $70,000) . |
| Meeting fees | None (no additional meeting attendance fees) | Not applicable . |
Notes: No additional fees for committee membership; chair retainers paid; US-style director pay model emphasizing equity alignment .
Performance Compensation (Director Equity)
| Item | Detail |
|---|---|
| Equity mix and value | Annual director equity value of $260,000; in FY2025 all non-executive directors elected 100% RSUs . |
| Grant timing | RSUs granted on annual meeting date (Nov 20, 2024 for FY2025) . |
| Vesting | RSUs vest in full on the earlier of: Nov 11 in the year after grant or the first annual meeting after grant; change-in-control full vesting if not continuing on successor board . |
| Deferral program | Directors may defer RSU settlement into Deferred Stock Units (DSUs); counts toward ownership; accelerated on change in control . |
| Performance metrics | Not applicable for non-executive director RSUs (time-based, no performance conditions) . |
Director Compensation (FY2025, Individual)
| Component | Amount |
|---|---|
| Fees earned or paid in cash | $73,190 . |
| RSUs (grant-date fair value) | $259,909 . |
| Options | $0 . |
| Other compensation | $0 . |
| Total | $333,099 . |
Other Directorships & Interlocks
- Current public company directorships: None .
- Compensation committee interlocks: None; no member of the compensation committee (including Gill) is/was an officer or employee; no interlocks requiring disclosure .
- Related-party or independence-impacting relationships: The board reported no specific relationships or transactions requiring consideration beyond the disclosed Farrell family relationship; Gill remains independent .
Expertise & Qualifications
- International consumer healthcare executive; extensive experience across Europe, Asia, and the Middle East in sales, marketing, and operations .
- Recognized compliance and quality oversight credentials through APACMed leadership; aligns with chairing ResMed’s CPQ Committee .
- Education: B.A. (Hons), University of Manchester .
Equity Ownership
| Measure | Detail |
|---|---|
| RSUs outstanding at FY2025 year-end | 1,083 . |
| Options outstanding at FY2025 year-end | 0 . |
| Deferred RSUs (DSUs) at FY2025 year-end | 0 . |
| Ownership guidelines | 5x annual cash retainer ($350,000 basis for FY2025); must retain 50% after-tax shares until compliant . |
| Compliance status (as of June 30, 2025) | All non-executive directors met guideline except DelOrefice (new director); implies Gill was in compliance . |
| Pledging/hedging | Prohibited for directors and officers . |
Governance Assessment
- Board effectiveness and independence: Gill strengthens the board’s independent oversight through chairing the expanded CPQ Committee (compliance, privacy, quality, sustainability) and serving on Audit and Compensation & Leadership Development, all with 100% FY2025 attendance—supportive of strong board process and risk oversight .
- Alignment and incentives: Director pay is US-peer aligned with equity-heavy mix; Gill’s FY2025 comp mix (cash $73.2k, RSUs $259.9k) shows meaningful “skin in the game” with vesting tied to service; ownership guideline compliance further aligns interests .
- Conflicts and red flags: No related-party exposures disclosed for Gill; independence affirmed; hedging/pledging prohibited; comp committee interlocks none—low governance risk profile for conflicts .
- Shareholder feedback context: Company-wide say‑on‑pay support was ~84% in Nov 2024 (up from ~82% in 2023), with management attributing variation partly to dual US/ASX listing dynamics; not director-specific, but indicative of broader governance dialogue .
RED FLAGS: None identified for Gill based on proxy disclosures—independence confirmed, full attendance, no related-party transactions, and compliance with ownership guidelines .